COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,580 Articles (22,415 medRxiv, 8,165 bioRxiv)

Most recent first Previous |  Page 1340: Articles 13391-13400  | Next

Modeling robust COVID-19 intensive care unit occupancy thresholds for imposing mitigation to prevent exceeding capacities
Runge, M., Richardson, R. A. K., Clay, P., Eagan, A., Holden, T. M., Singam, M., Tsuboyama, N., Arevalo, P., Fornoff, J., Patrick, S., Ezike, N. O., Gerardin, J.
10.1101/2021.06.27.21259530 — Posted: 2021-07-03
SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted.
Rovida, F., Cassaniti, I., Paolucci, S., Percivalle, E., Sarasini, A., Piralla, A., Giardina, F., Sammartino, J. C., Ferrari, A., Bergami, F., Muzzi, A., Novelli, V., Meloni, A., Grugnetti, A. M., Grugnetti, G., Rona, C., Daglio, M., Marena, C., Triarico, A., Lilleri, D., Baldanti, F.
10.1101/2021.06.29.21259500 — Posted: 2021-07-03 Discussion: Onsite | Offsite
Longitudinal testing for SARS-CoV-2 RNA in day care centers in Hesse, Germany, during increased local incidence and with VOC Alpha as dominant variant: Results of the SAFE KiDS 2 and SAFE KiDS 3 study
Schenk, B., Hoehl, S., Rudych, O., Kreutzer, E., Menger, D., Farmand, S., Gebert, D., Flohr, M., Berger, F., Wrobel, F., Weigel, V., Kortenbusch, M., Berger, A., Ciesek, S.
10.1101/2021.06.29.21259633 — Posted: 2021-07-03
Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
Begin, P., Callum, J., Jamula, E. J., Cook, R., Heddle, N. M., Tinmouth, A., Zeller, M. P., Beaudoin-Bussiere, G., Amorim, L., Bazin, R., Cadogan Lofstgard, K., Carl, R., Chasse, M., Cushing, M., Daneman, N., Devine, D. V., Dumaresq, J., Ferguson, D., Gabe, C., Glesby, M. J., Li, N., Liu, Y., McGeer, A., Robitaille, N., Sachais, B. S., Scales, D. C., Schwartz, L., Shehata, N., Turgeon, A., Wood, H., Zarychanski, R., Finzi, A., Arnold, D. M., CONCOR-1 Study Group
10.1101/2021.06.29.21259427 — Posted: 2021-07-03
Prospective sero surveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India
Njarekkattuvalappil, S. K., Bhaskaran, R., Vijaya Raj, S. R., Jose, P., Rafi, A. M., Thomas, J., Innah, S., Raphael, L., G, U. U., R, P., Valsan, C., Kuttichira, P.
10.1101/2021.06.29.21259686 — Posted: 2021-07-03
SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R.
10.1101/2021.07.02.450959 — Posted: 2021-07-03
The drop in reported invasive pneumococcal disease among adults during the first COVID-19 wave in the Netherlands explained.
Dirkx, K. K. T., Mulder, B., Post, A., Rutten, M., Swanink, C., Wertheim, H., Cremers, A.
10.1101/2021.06.29.21259494 — Posted: 2021-07-03
Placental vascular remodeling in pregnant women with COVID-19
Gychka, S. G., Kuchyn, I. L., Savchuk, T. V., Nikolaienko, S. I., Zhezhera, V. M., Chermak, I. I., Suzuki, Y. J.
10.1101/2021.07.01.21259860 — Posted: 2021-07-03
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial
Ella, R., Reddy, S., Blackwelder, W., Potdar, V., Yadav, P., Sarangi, V., Aileni, V. K., Kanungo, S., Rai, S., Reddy, P., Verma, S., Singh, C., Redkar, S., Mohapatra, S., Pandey, A., Ranganadin, P., Gumashta, R., Multani, M., Mohammad, S., Bhatt, P., Kumari, L., Sapkal, G., Gupta, N., Abraham, P., Panda, S., Prasad, S., Bhargava, B., Ella, K., Vadrevu, K. M., COVAXIN Study Group
10.1101/2021.06.30.21259439 — Posted: 2021-07-02 Discussion: Onsite
The safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-associated pneumonia: a systematic review and meta-analysis
Wang, J., Shi, P., Chen, D., Wang, S., Wang, P., Feng, X., Zhang, L.
10.1101/2021.07.01.21259838 — Posted: 2021-07-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).